Sencillo y complejo | 25 FEB 13

Un extraño caso de infarto de miocardio

Este caso enseña que hasta las manifestaciones iniciales aparentemente sencillas de una enfermedad común pueden implicar una enfermedad de base más compleja. ¿Cómo actuar ante un infarto con leucocitosis y trombocitosis?
Autor/a: Dres. Leng S, Nallamothu BK, Saint S, Appleman LJ, Bump GM. N Engl J Med 2013;368:65-71
INDICE:  1. Artículo | 2. Referencias
Referencias

Referencias
1. Kardasz I, De Caterina R. Myocardial infarction with normal coronary arteries: a conundrum with multiple aetiologies and variable prognosis: an update. J Intern Med 2007;261:330-48.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22:14-22.
3. Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders.  Blood Rev 2010;24:227-32.
4. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008; 22:2020-8.
5. Barbui T. How to manage thrombosis in myeloproliferative neoplasms. Curr Opin
Oncol 2011; 23:654-8.
6. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115:778-82.
7. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114-24.
8. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;
355:2452-66.
9. Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management  of  adults and children presenting with a thrombocytosis. Br J Haematol 2010; 149:352-75.
10. Schafer AI. Thrombocytosis. N Engl J Med 2004; 350:1211-9.
11. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29:3179-84.
12. Marchioli R, Finazzi G, Specchia G, et inal. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
13. Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87:285-93.
14. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366:799-807.
15. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366:787-98.
16. Tefferi A, Pardanani A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood Rev 2011; 25:229-37.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024